DPC-083. DuPont Pharmaceuticals.
DPC-083 and DPC-961 are non-nucleoside reverse transcriptase inhibitors (NNRTIs) under development by DuPont Pharmaceuticals for the potential treatment of HIV infection [312865]. Phase I trials were completed by September 2000 [383661], and by April 2001, DPC-083 was in phase II trials as a once-daily oral dose in combination therapy, with phase III studies expected to begin in the third quarter of 2001 [392761]. NDA filing is anticipated for 2003, for which the company would expect an FDA expedited review [405548]. DPC-083 and DPC-961 possess antiviral activity against mutant variants of HIV-1, including the K103N mutant, and have the same potency as efavirenz against wild-type virus in rhesus monkeys [312865]. DuPont has also described a series of novel tricyclic quinazolinones which were found to possess noteworthy biological activity during investigation of DPC-083 and DPC-961.
Lim
M L
ML
University of California at San Francisco, Department of Clinical Pharmacy, 521 Pamassus Avenue, C-152, Box 0622, San Francisco, CA 94143-0622, USA. michaelleelim@hotmail.com
D019380:Anti-HIV Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D011799:Quinazolines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D019380:Anti-HIV Agents; C430648:DPC 083; D011799:Quinazolines; D018894:Reverse Transcriptase Inhibitors